Chromocell Therapeutics, a clinical-stage biotech based in New Jersey, focuses on developing pain therapeutics targeting the NaV1.7 sodium channel, with its lead compound CC8464 completing Phase I studies. The company went public on February 16, 2024, and employs four full-time staff.
Richard Malamut bought 10,400 shares of CHRO on 12 September at $0.94 per share, worth a total of $10K. They now own 91,565 CHRO shares, or a 13% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
